NCM
Nantahala Capital Management Portfolio holdings
AUM
$1.41B
This Quarter Return
+9.78%
1 Year Return
+32.9%
3 Year Return
+104.34%
5 Year Return
+145.08%
10 Year Return
+443.66%
AUM
$1.43B
AUM Growth
+$1.43B
(+20%)
Cap. Flow
+$76.4M
Cap. Flow
% of AUM
5.35%
Top 10 Holdings %
Top 10 Hldgs %
42.88%
Holding
145
New
15
Increased
42
Reduced
27
Closed
17
Top Buys
| 1 |
Hilton Grand Vacations
HGV
|
$38.3M |
| 2 |
Soleno Therapeutics
SLNO
|
$29.6M |
| 3 |
iShares Russell 2000 ETF
IWM
|
$21.1M |
| 4 |
SVC
Service Properties Trust
SVC
|
$20.6M |
| 5 |
The Bancorp
TBBK
|
$20.3M |
Top Sells
| 1 |
OPTN
OptiNose
OPTN
|
$89.3M |
| 2 |
Establishment Labs
ESTA
|
$32.5M |
| 3 |
Peloton Interactive
PTON
|
$27.2M |
| 4 |
PWSC
PowerSchool Holdings, Inc.
PWSC
|
$13.3M |
| 5 |
BlackSky Technology
BKSY
|
$11.6M |
Sector Composition
| 1 | Healthcare | 62.01% |
| 2 | Consumer Discretionary | 14.94% |
| 3 | Communication Services | 6.55% |
| 4 | Financials | 6.13% |
| 5 | Industrials | 3.46% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Syndax Pharmaceuticals
SNDX
$1.41B
| $7.41M | 0.32% | 560,532 +107,300 | +24% | +$1.42M |
|
52
Nektar Therapeutics
NKTR
$568M
| $7.26M | 0.31% | 7,810,000 +3,700,000 | +90% | +$3.44M |
|
|
SLN
53
Silence Therapeutics
SLN
$227M
| $7.22M | 0.31% | 1,049,676 +849,676 | +425% | +$5.85M |
|
54
Inhibikase Therapeutics
IKT
$134M
| $7.12M | 0.31% | +2,190,000 | New | +$7.12M |
|
55
Assertio
ASRT
$80.4M
| $7.1M | 0.3% | 8,148,336 -800,000 | -9% | -$697K |
|
56
Cogent Biosciences
COGT
$1.69B
| $6.65M | 0.29% | 852,855 +61,919 | +8% | +$483K |
|
|
OPTN
57
DELISTED
OptiNose
OPTN
| $6.59M | 0.28% | 986,031 -13,370,672 | -93% | -$89.3M |
|
58
Neuropace
NPCE
$303M
| $6.29M | 0.27% | 562,073 -45,817 | -8% | -$513K |
|
59
The ONE Group
STKS
$86.4M
| $6.05M | 0.26% | 2,087,394 +403,321 | +24% | +$1.17M |
|
60
Astria Therapeutics
ATXS
$349M
| $6.03M | 0.26% | 675,000 | – | – |
|
61
Structure Therapeutics
GPCR
$1.11B
| $5.99M | 0.26% | 221,000 +50,000 | +29% | +$1.36M |
|
62
VistaGen Therapeutics
VTGN
$102M
| $5.85M | 0.25% | 1,981,980 +464,284 | +31% | +$1.37M |
|
63
Fossil Group
FOSL
$165M
| $5.56M | 0.24% | 3,326,677 +1,421,399 | +75% | +$2.37M |
|
64
Alta Equipment Group
ALTG
$267M
| $5.53M | 0.24% | 845,115 | – | – |
|
65
Amylyx Pharmaceuticals
AMLX
$836M
| $5.49M | 0.24% | 1,452,153 +47,589 | +3% | +$180K |
|
|
THRD
66
DELISTED
Third Harmonic Bio
THRD
| $5.16M | 0.22% | +501,000 | New | +$5.16M |
|
67
Anebulo Pharmaceuticals
ANEB
$103M
| $5.1M | 0.22% | 3,036,325 +2,525,252 | +494% | +$4.24M |
|
68
Xtant Medical Holdings
XTNT
$83.3M
| $5.05M | 0.22% | 11,394,000 | – | – |
|
69
Apyx Medical
APYX
$75.3M
| $5.01M | 0.22% | +3,169,800 | New | +$5.01M |
|
70
Lexicon Pharmaceuticals
LXRX
$400M
| $4.88M | 0.21% | 6,604,150 +4,300,000 | +187% | +$3.18M |
|
|
THTX
71
Theratechnologies
THTX
$149M
| $4.85M | 0.21% | 2,682,228 | – | – |
|
72
NN Inc
NNBR
$129M
| $4.77M | 0.2% | 1,458,416 | – | – |
|
73
Eledon Pharmaceuticals
ELDN
$155M
| $4.73M | 0.2% | 1,147,946 +547,946 | +91% | +$2.26M |
|
74
EyePoint Pharmaceuticals
EYPT
$797M
| $4.47M | 0.19% | +600,000 | New | +$4.47M |
|
75
InspireMD
NSPR
$102M
| $4.4M | 0.19% | 1,674,565 -535,028 | -24% | -$1.41M |
|